Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.9MCash on Hand
3.6mo Cash Runway
Follow DWTX by emailGet an email when DWTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DWTX, unsubscribe in one click. Privacy
📣 What DWTX Says Is Next
in November 2026 · Halneuron: “Top-line results are expected to be announced in November 2026.”
Company press release, Nov 5, 2026 · SEC filing
this fall · ““Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress for both Halneuron ® , with Phase 2b data anticipated this fall, and SP16, which received FDA clearance to progress into Phase 1b development this quarter , ” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics.”
Company press release, May 14, 2026 · SEC filing
the end of 2026 · “Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron ® Phase 2b program.”
Company press release, Mar 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: licensing revenue of $0.1 million, R&D of $3.3 million (vs $14.5 million), G&A of $1.6 million, and net loss of $4.9 million, or $0.14 per share. Cash of $4.9 million plus a $5 million private placement gives runway through Q1 2027. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Financing Registers resale of up to 4,098,360 common shares by Sealbond Limited, bought in an Oct 19, 2026 private placement at $1.22 per share for about $5.0 million. The company will not receive any proceeds from these resales. Form S-3 · SEC filing
Oct 19, 2026 ·
Financing Dogwood agreed to sell 4,098,360 shares to its largest shareholder, Sealbond Limited, at $1.22 per share for about $5 million in a private placement, expected to close on or before October 29, 2026. Proceeds go to working capital. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Dogwood reported Q2 2026 net loss attributable to common stockholders of $11.5 million, or $0.34 per share, including a $6.7 million net non-cash IPR&D and goodwill impairment. Cash on hand is $9.6 million, with Halneuron Phase 2b topline results expected in fall 2026 and 217 patients enrolled. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2 · Active Trial · Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
DWTX holds $4.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.1M/quarter from operations,
an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 4 months +40
ATM program on file since Nov 2025 +15
Shelf registration (S-3, May 2025) +10
Raised after last reported balance sheet (Oct 2026) -10
Share count 38,227,913 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DWTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DWTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.